J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study

​J&J has reported that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase II JASMINE study by reducing disease activity in adults with moderate-to-severe SLE.

The post J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.